As the opioid crisis accelerated a decade ago, pharmaceutical sales reps emphasized the benefits of the addictive painkillers, but rarely mentioned serious harms — and physicians generally believed the information was sufficiently useful to consider additional prescribing, according to a new analysis.

Specifically, the health benefits of opioids — such as tramadol and hydromorphone — were discussed in 78% of the interactions, but in 54% of the meetings, adverse events were not mentioned. Serious adverse events did come up, but in only 12% of the encounters. Meanwhile, safety claims, such as statements that the pills were well tolerated, were mentioned nearly half of the time, or 49%.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy